Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Completed 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 16INDUSTRY 5NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 13CNS 13NET 5Gastrointestinal 2Genitourinary 1

Conditions

Neuroendocrine Tumors 117Gastro-enteropancreatic neuroendocrine tumor 21Neoplasms 20Carcinoid Tumor 17Colorectal Neoplasms 13Carcinoma, Neuroendocrine 11Neoplasm Metastasis 10Carcinoma 10Lung Neoplasms 9Small Cell Lung Carcinoma 8Prostatic Neoplasms 8Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Sarcoma 7Pancreatic Neoplasms 7Carcinoma, Hepatocellular 7Adenoma, Islet Cell 7Stomach Neoplasms 6Serotonin Syndrome 6Pheochromocytoma 6Melanoma 6Head and Neck Neoplasms 6Digestive System Neoplasms 6Cholangiocarcinoma 6Thyroid Neoplasms 5Paraganglioma 5Ovarian Neoplasms 5Gastroenteropancreatic Neuroendocrine Tumors 5Colonic Neoplasms 5

Interventions

3-Iodobenzylguanidine 2lutetium Lu 177 dotatate 1copper dotatate CU-64 1Lutetium-177 1Lutetium 1Iodine-131 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Paraganglioma × NET × Clear all
NCT05636618 2026-05-14

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Perspective Therapeutics

Phase 1/2 Recruiting
300 enrolled
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00458952 2016-07-13

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 1/2 Completed
24 enrolled 8 charts
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00339131 2011-10-12

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

Molecular Insight Pharmaceuticals, Inc.

Phase 1 Completed
24 enrolled
CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡